Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline 2026.1.0

Dr. Jennifer Caswell-Jin and Dr. Michael Hassett join the podcast to introduce the new living guideline, "Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer." As co-chairs of the expert panel, they provide a comprehensive overview of the guideline's scope and purpose, which consolidates recommendations from multiple previous ASCO guidelines into a single, regularly updated resource. Drs. Caswell-Jin and Hassett discuss the key recommendations for neoadjuvant and adjuvant therapies, including chemotherapy, endocrine therapy, and targeted therapies like CDK4/6 inhibitors and olaparib. They explain the guideline's novel framework for estimating prognosis and using absolute risk to guide individualized treatment decisions. The discussion also covers ongoing research the panel is monitoring for future updates, such as the Keynote-756 and lidERA trials, and the potential role of circulating tumor DNA tests.

Read the full living guideline, "Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026 1.0," at www.ascopubs.org/guidelines."

LINK TO FULL TRANSCRIPT